Attached files
file | filename |
---|---|
8-K - FORM 8-K - SEELOS THERAPEUTICS, INC. | d871082d8k.htm |
EX-99.1 - EX-99.1 - SEELOS THERAPEUTICS, INC. | d871082dex991.htm |
EX-10.1 - EX-10.1 - SEELOS THERAPEUTICS, INC. | d871082dex101.htm |
EX-4.1 - EX-4.1 - SEELOS THERAPEUTICS, INC. | d871082dex41.htm |
EX-10.2 - EX-10.2 - SEELOS THERAPEUTICS, INC. | d871082dex102.htm |
EX-5.1 - EX-5.1 - SEELOS THERAPEUTICS, INC. | d871082dex51.htm |
Exhibit 5.2
12670 High Bluff Drive | ||||
San Diego, California 92130 | ||||
Tel: +1.858.523.5400 Fax: +1.858.523.5450 | ||||
www.lw.com | ||||
February 12, 2015 | FIRM / AFFILIATE OFFICES | |||
Abu Dhabi | Milan | |||
Barcelona | Moscow | |||
Beijing | Munich | |||
Boston | New Jersey | |||
Brussels | New York | |||
Century City | Orange County | |||
Chicago | Paris | |||
Doha | Riyadh | |||
Dubai | Rome | |||
Düsseldorf | San Diego | |||
Apricus Bioscience, Inc. | Frankfurt | San Francisco | ||
11975 El Camino Real, Suite 300 | Hamburg | Shanghai | ||
San Diego, CA 92130 | Hong Kong | Silicon Valley | ||
Houston | Singapore | |||
London | Tokyo | |||
Re: Apricus Biosciences, Inc. Offering of Common Stock and Warrants |
Los Angeles | Washington, D.C. | ||
Madrid |
Ladies and Gentlemen:
We have acted as special counsel to Apricus Biosciences, Inc., a Nevada corporation (the Company), in connection with the sale to the purchasers (the Purchasers) of (i) 6,043,955 shares of common stock of the Company, par value $0.001 per share (the Common Stock), and (ii) warrants to purchase up to 3,021,977 shares of Common Stock (the Warrants), pursuant to (i) a registration statement on Form S-3 under the Securities Act of 1933, as amended (the Act), filed with the Securities and Exchange Commission (the Commission) on August 12, 2014 (Registration No. 333-198066) (as so filed and as amended, the Registration Statement), (ii) a base prospectus, dated August 25, 2014 (the Base Prospectus), (iii) a prospectus supplement, dated February 10, 2015, filed with the Commission pursuant to Rule 424(b) under the Act (the Prospectus Supplement and, together with the Base Prospectus, the Prospectus) and (iv) the subscription agreements, each dated as of February 10, 2015, between the Purchasers and the Company (the Subscription Agreements). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or Prospectus, other than as expressly stated herein with respect to the issue of the Warrants.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction, or as to any matters of municipal law or the laws of any local agencies within any state.
February 12, 2015
Page 2
Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Warrants have been duly executed, authenticated, issued and delivered against payment therefor in the circumstances contemplated by the Subscription Agreements (assuming the due authorization, execution and delivery of the Warrants by the Company, and assuming the securities issuable upon exercise of such Warrants have been duly authorized and reserved for issuance by all necessary corporate action), the Warrants will be legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
Our opinions are subject to: (i) the effect of bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; and (ii) the effect of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), concepts of materiality, reasonableness, good faith and fair dealing, and the discretion of the court before which a proceeding is brought. We express no opinion or confirmation as to federal or state securities laws, tax laws, antitrust or trade regulation laws, insolvency or fraudulent transfer laws, antifraud laws, compliance with fiduciary duty requirements, pension or employee benefit laws, FINRA rules or stock exchange rules (without limiting other laws excluded by customary practice).
This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Companys Current Report on Form 8-K dated February 12, 2015 and to the reference to our firm in the Prospectus under the heading Legal Matters. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
Very truly yours, |
/s/ Latham & Watkins LLP |